BRIEF-Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review

Feb 12 (Reuters) - Pfizer Inc:

* U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZER’S THIRD-GENERATION ALK INHIBITOR LORLATINIB

* PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW Source text for Eikon: Further company coverage: